Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 4839

Similar articles for PubMed (Select 15937142)

1.

Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.

Brando C, Mukhopadhyay S, Kovacs E, Medina R, Patel P, Catina TL, Campbell KS, Santoli D.

J Leukoc Biol. 2005 Aug;78(2):359-71. Epub 2005 Jun 3.

2.

Live cell evaluation of granzyme delivery and death receptor signaling in tumor cells targeted by human natural killer cells.

Vrazo AC, Hontz AE, Figueira SK, Butler BL, Ferrell JM, Binkowski BF, Li J, Risma KA.

Blood. 2015 Jun 29. pii: blood-2015-03-632273. [Epub ahead of print]

PMID:
26124495
3.
4.

Fcγ-receptor tag team boosts anti-tumor immunity.

Arce Vargas F, Quezada SA.

Trends Immunol. 2015 Jun 16. pii: S1471-4906(15)00145-3. doi: 10.1016/j.it.2015.06.001. [Epub ahead of print]

PMID:
26091729
5.

Expression, crystallization and X-ray diffraction analysis of a complex between B7-H6, a tumor cell ligand for the natural cytotoxicity receptor NKp30, and an inhibitory antibody.

Xu X, Li Y, Gauthier L, Chen Q, Vivier E, Mariuzza RA.

Acta Crystallogr F Struct Biol Commun. 2015 Jun 1;71(Pt 6):697-701. doi: 10.1107/S2053230X15006755. Epub 2015 May 20.

PMID:
26057798
6.

Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.

Pittari G, Filippini P, Gentilcore G, Grivel JC, Rutella S.

Front Immunol. 2015 May 13;6:230. doi: 10.3389/fimmu.2015.00230. eCollection 2015. Review.

7.

Increased co-expression of the natural killer cell receptor NKG2D and further natural killer cell receptors on CD4⁺ T cells in granulomatosis with polyangiitis.

Schüler S, Wolters S, Pitann S, Kabelitz D, Lamprecht P.

Clin Exp Rheumatol. 2015 Mar-Apr;33(2 Suppl 89):S-183-4. Epub 2015 May 26. No abstract available.

PMID:
26016770
8.

Transfer of the human NKG2D ligands UL16 binding proteins (ULBP) 1-3 is related to lytic granule release and leads to ligand retransfer and killing of ULBP-recipient natural killer cells.

López-Cobo S, Romera-Cárdenas G, García-Cuesta EM, Reyburn HT, Valés-Gómez M.

Immunology. 2015 May 14. doi: 10.1111/imm.12482. [Epub ahead of print]

PMID:
25980678
9.

Therapeutic potential and challenges of natural killer cells in treatment of solid tumors.

Gras Navarro A, Björklund AT, Chekenya M.

Front Immunol. 2015 Apr 29;6:202. doi: 10.3389/fimmu.2015.00202. eCollection 2015. Review.

10.

Utilizing chimeric antigen receptors to direct natural killer cell activity.

Hermanson DL, Kaufman DS.

Front Immunol. 2015 Apr 28;6:195. doi: 10.3389/fimmu.2015.00195. eCollection 2015. Review.

11.

STAT1-S727 - the license to kill.

Putz EM, Gotthardt D, Sexl V.

Oncoimmunology. 2014 Dec 13;3(9):e955441. eCollection 2014 Oct.

PMID:
25941617
12.

Expression of activating receptors on natural killer cells from AIDS-related lymphoma patients.

Mercier-Bataille D, Sanchez C, Baier C, Le Treut T, Mounier N, Mokhtari S, Olive D, Baumstarck K, Sébahoun G, Besson C, Costello RT.

AIDS Res Ther. 2014 Nov 24;11:38. doi: 10.1186/1742-6405-11-38. eCollection 2014.

13.

Distinct mechanisms of tumor resistance to NK killing: of mice and men.

Pardoll DM.

Immunity. 2015 Apr 21;42(4):605-6. doi: 10.1016/j.immuni.2015.04.007.

PMID:
25902479
14.

Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.

Figueroa JA, Reidy A, Mirandola L, Trotter K, Suvorava N, Figueroa A, Konala V, Aulakh A, Littlefield L, Grizzi F, Rahman RL, Jenkins MR, Musgrove B, Radhi S, D'Cunha N, D'Cunha LN, Hermonat PL, Cobos E, Chiriva-Internati M.

Int Rev Immunol. 2015 Mar;34(2):154-87. doi: 10.3109/08830185.2015.1018419.

PMID:
25901860
15.

Central nervous system acute lymphoblastic leukemia: role of natural killer cells.

Frishman-Levy L, Shemesh A, Bar-Sinai A, Ma C, Ni Z, Frenkel S, Muench V, Bruckmueller H, Vokuhl C, Debatin KM, Eckert C, Stanulla M, Schrappe M, Campbell KS, Loewenthal R, Schewe DM, Hochman J, Meyer LH, Kaufman D, Cario G, Porgador A, Izraeli S.

Blood. 2015 May 28;125(22):3420-31. doi: 10.1182/blood-2014-08-595108. Epub 2015 Apr 20.

PMID:
25896649
16.

Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy.

Granzin M, Soltenborn S, Müller S, Kollet J, Berg M, Cerwenka A, Childs RW, Huppert V.

Cytotherapy. 2015 May;17(5):621-32. doi: 10.1016/j.jcyt.2015.03.611.

17.
18.

Pemphigus is associated with KIR3DL2 expression levels and provides evidence that KIR3DL2 may bind HLA-A3 and A11 in vivo.

Augusto DG, O'Connor GM, Lobo-Alves SC, Bass S, Martin MP, Carrington M, McVicar DW, Petzl-Erler ML.

Eur J Immunol. 2015 Apr 13. doi: 10.1002/eji.201445324. [Epub ahead of print]

PMID:
25867094
20.

Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells.

Boerman GH, van Ostaijen-ten Dam MM, Kraal KC, Santos SJ, Ball LM, Lankester AC, Schilham MW, Egeler RM, van Tol MJ.

Cancer Immunol Immunother. 2015 May;64(5):573-83. doi: 10.1007/s00262-015-1657-9. Epub 2015 Feb 18.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk